Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 8:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 1 Interventional Results available

PVSRIPO for Recurrent Glioblastoma (GBM)

NCT01491893
Conditions
GBM, Glioblastoma, Glioma, Malignant Glioma
Interventions
Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)
Biological
Lead sponsor
Istari Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Completed Phase 2 Interventional Results available

Lerapolturev in Recurrent Malignant Glioma

NCT02986178
Conditions
Malignant Glioma
Interventions
lerapolturev, Lomustine
Biological · Drug
Lead sponsor
Istari Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
6
States / cities
San Francisco, California • Jacksonville, Florida • Boston, Massachusetts + 2 more
Conditions
Malignant Glioma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Glioblastoma, Gliosarcoma, Atypical Teratoid/Rhabdoid Tumor of Brain, Medulloblastoma, Ependymoma, Pleomorphic Xanthoastrocytoma of Brain, Embryonal Tumor of Brain
Interventions
Polio/Rhinovirus Recombinant (PVSRIPO)
Biological
Lead sponsor
Istari Oncology, Inc.
Industry
Eligibility
12 Years to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Solid Tumor, Bladder Cancer, Non-muscle-invasive Bladder Cancer
Interventions
Lerapolturev, 5% DDM
Biological · Other
Lead sponsor
Istari Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Myrtle Beach, South Carolina
Recruiting Phase 2 Interventional

Lerapolturev (PVSRIPO) in GBM

NCT06177964
Conditions
Recurrent Supratentorial Glioblastoma
Interventions
Lerapolturev, Lomustine Pill
Drug
Lead sponsor
Darell Bigner
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Melanoma
Interventions
PVSRIPO, Nivolumab
Biological · Drug
Lead sponsor
Darell Bigner
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Glioblastoma, Recurrent Glioblastoma, Supratentorial Glioblastoma, Brain Tumor
Interventions
lerapolturev, pembrolizumab
Biological
Lead sponsor
Istari Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
10
States / cities
San Francisco, California • Farmington, Connecticut • Jacksonville, Florida + 5 more
Terminated Phase 1 Interventional Results available

PVSRIPO for Patients With Unresectable Melanoma

NCT03712358
Conditions
Melanoma
Interventions
PVSRIPO
Biological
Lead sponsor
Istari Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Melanoma
Interventions
Lerapolturev, Anti-PD-1 Checkpoint Inhibitor
Biological
Lead sponsor
Istari Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
12
States / cities
Scottsdale, Arizona • Orlando, Florida • Chicago, Illinois + 9 more
Completed Early Phase 1 Interventional Results available

Examining Bioactivity of PVSRIPO in Invasive Breast Cancer

NCT03564782
Conditions
Invasive Breast Cancer
Interventions
PVSRIPO
Biological
Lead sponsor
Istari Oncology, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Durham, North Carolina